Skip to main content
Premium Trial:

Request an Annual Quote

RNAi Delivery Firm Traversa Raises $2M

NEW YORK (GenomeWeb News) – Traversa Therapeutics, a La Jolla, Calif.-based developer of RNAi delivery technologies, today announced that it has raised $2 million in a Series A financing round.
 
Traversa’s technology was developed by Steven Dowdy, a Howard Hughes Medical Institute investigator at the University of California, San Diego.
 
“The technology has received an outstanding level of interest for use with human therapeutics, and as a high-throughput screening reagent, providing the company with both long-term growth prospects and a short-term revenue stream to augment this financing,” Hans Petersen, president and CEO of Traversa, said in a statement.
 
The financing was led by San Diego Tech Coast Angels, with additional funding coming from Mesa Verde Venture Partners and Morningside Group.
 
The firm also said that Francois Ferre, co-CEO of Althea and lead angel investor, has joined its board.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.